Business Wire

Nord Anglia Education and Boston College to Demonstrate the Power of Metacognition at the European Conference on Education

Share

Dr Kate Erricker, Group Head of Education Research and Global Partnerships at Nord Anglia Education, and Dr Damian Bebell, Assistant Professor at the Lynch School of Education and Human Development, Boston College, will lead a workshop on metacognition at the European Conference on Education (ECE) on Saturday 13 July 2024.

Titled “Exploring the Implementation and Outcomes of a Global Metacognition Project”, the workshop will explore how metacognition can improve learning in classrooms and showcase Nord Anglia Education’s pioneering metacognition research project involving 27 schools in 17 countries.

Metacognition is being aware of and controlling one’s own learning processes. Studies have shown that metacognition can greatly enhance student learning.

“Metacognition bridges the gap between knowledge and understanding,” says Dr Kate Erricker. “By teaching students to be aware of how they think and learn, we’re not just enhancing their academic performance but also preparing them for future challenges.”

Emma Coleman, Research Lead at Nord Anglia Education, is working with the participating schools to integrate metacognitive strategies. She explains: “By embedding metacognitive practices into everyday classroom activities, we’re creating a generation of learners who are not only academically capable but also self-aware and resilient. This project showcases the incredible potential of reflective learning on a global scale.”

The workshop will give educators practical tools and insights to bring metacognitive practices into their classrooms to improve student learning and engagement. The participating Nord Anglia schools offer valuable lessons on the benefits and challenges of using metacognition in different international settings, which participants may not have had access to elsewhere.

Dr Damian Bebell says: “Our metacognition research with Nord Anglia seeks to create a more reflective and adaptable learning environment. By understanding their own thought processes, students and their teachers can take control of their educational journey and thrive in diverse settings.”

About Nord Anglia Education:

As a leading international schools organisation, we're shaping a generation of creative and resilient global citizens who graduate from our schools with everything they need for success, whatever they choose to be or do in life.

Our strong academic foundations combine world-class teaching and curricula with cutting-edge technology and facilities, creating learning experiences like no other. Inside and outside of the classroom, we inspire our students to achieve more than they ever thought possible.

No two children learn the same way, which is why our schools around the world personalise learning to what works best for every student. Inspired by our high-quality teachers, our students achieve outstanding academic results and go on to study at the world's top universities.

To learn more or apply for a place for your child, go to www.nordangliaeducation.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240712466125/en/

Contacts

Media enquiries:
Francesca Milani
Communications Manager
+44 20 7131 0000
francesca.milani@nordanglia.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Coulson Aviation Announces Launch of Boeing 767 VLAT Program22.12.2025 15:03:00 EET | Press release

Coulson Aviation USA has announced the launch of its Boeing 767 Very Large Airtanker (VLAT) program, marking a significant advancement in the evolution of aerial firefighting capability. The program is intended to provide a sustainable replacement for legacy VLAT platforms nearing the end of their operational service life. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251222917730/en/ A cross-sectional view of Coulson Aviation’s Boeing 767 Very Large Airtanker (VLAT) illustrates the integration of the RADS retardant delivery system and the next generation of high-capacity, sustainable aerial firefighting design. The recent grounding of the MD11 and DC10 fleets has highlighted a structural challenge for firefighting agencies worldwide. As older widebody aircraft are retired, the industry faces a significant reduction in high-capacity, large-scale retardant delivery capability. Coulson’s 767 VLAT is being developed to address

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye